Automating Cardiology Specialty Drug Prior Auth Workflows

Klivira optimizes cardiology specialty drug prior auth processes, reducing administrative burden and accelerating patient access to critical cardiovascular therapies.

Managing prior authorizations for high-cost specialty cardiovascular drugs presents unique challenges, from navigating complex step-therapy protocols to determining the correct benefit channel. For revenue cycle directors and prior authorization coordinators, these complexities can lead to significant delays and denials. Klivira provides a robust solution designed to integrate seamlessly into existing cardiology workflows.

The Landscape of Cardiology Specialty Drugs Requiring PA

Specialty cardiovascular drugs, including PCSK9 inhibitors, sacubitril/valsartan, SGLT2 inhibitors for heart failure indications, and mavacamten for hypertrophic cardiomyopathy, often require prior authorization due to their high cost and specific use criteria. These therapies are critical for managing complex cardiac conditions but frequently trigger stringent payer reviews. Klivira's platform is engineered to address the distinct PA requirements associated with these vital medications.

Navigating Medical vs. Pharmacy Benefit for Cardiovascular Therapies

A primary challenge in cardiology specialty drug prior auth is accurately determining whether a specific medication falls under the medical or pharmacy benefit. This distinction dictates the submission channel, whether through a PBM's ePA process via NCPDP SCRIPT or a medical PA channel like X12 278 or Da Vinci PAS. Klivira automates this critical benefit-side determination per drug, per payer, and per patient context, preventing misclassification errors.

Key Documentation Requirements for Cardiology Specialty Drug PAs

**PCSK9 Inhibitors:** Documentation of LDL on maximum tolerated statin therapy plus ezetimibe trial.
**Sacubitril/Valsartan:** Evidence of Heart Failure with Reduced Ejection Fraction (HFrEF).
**SGLT2 Inhibitors for HF:** Ejection fraction or documented HFpEF criteria.
**Mavacamten:** Specific hypertrophic cardiomyopathy diagnostic criteria and symptom burden.
Comprehensive prior-line therapy history to satisfy step-therapy requirements.

Common Denial Vectors for Cardiovascular Specialty Drug PAs

Denials for cardiology specialty drug prior authorizations frequently stem from inadequate documentation of step-therapy completion or missing clinical criteria, such as ejection fraction or NYHA functional class. Site-of-care policies, steering infusions away from hospital outpatient settings, also contribute to denials. Klivira's system proactively identifies these potential issues and guides users to provide the necessary information before submission.

Klivira's Automated Approach to Cardiology Specialty Drug PA

Klivira streamlines the cardiology specialty drug prior auth workflow by automating benefit-side determination and routing requests through appropriate channels, including NCPDP SCRIPT ePA for pharmacy benefits and FHIR PAS or X12 278 for medical benefits. The platform reads medication history from FHIR MedicationRequest resources to populate step-therapy documentation, integrates site-of-care logic, and coordinates post-approval specialty pharmacy fulfillment. This comprehensive automation reduces manual effort and accelerates patient access to life-saving cardiovascular drugs.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for cardiology specialty drugs?

Klivira's policy engine automatically identifies the correct benefit side (medical vs. pharmacy) for each cardiology specialty drug, based on the specific drug, payer, and patient context. This ensures accurate routing to either PBM ePA channels (NCPDP SCRIPT) or medical PA channels (X12 278, Da Vinci PAS), preventing submission errors and delays.

What specific cardiology drugs does Klivira support for PA automation?

Klivira supports prior authorization automation for a range of cardiology specialty drugs, including PCSK9 inhibitors, sacubitril/valsartan, SGLT2 inhibitors for heart failure indications, and mavacamten. Our platform integrates payer-specific step-therapy logic and documentation requirements for these high-cost cardiovascular therapies.

How does Klivira address step-therapy requirements for cardiovascular biologics?

Klivira automates the documentation of step-therapy and prior-line therapy history for cardiovascular biologics and other specialty drugs. By reading medication history and treatment-response data from FHIR MedicationRequest and Observation resources, the platform ensures that all necessary prior treatment information is accurately included in the PA submission, aligning with payer guidelines.

Can Klivira integrate with our EMR for cardiology PA workflows?

Yes, Klivira is designed for deep integration with leading EMR systems. This allows for seamless data exchange, pulling relevant clinical documentation directly from the EMR to support cardiology specialty drug PA submissions and pushing PA status updates back into the patient record, minimizing manual data entry and improving workflow efficiency.

What role does site-of-care play in cardiology specialty drug PAs?

For medical-benefit cardiology specialty drugs, many payers enforce site-of-care policies, often steering infusions away from higher-cost hospital outpatient settings. Klivira's PA submission process incorporates site-of-care logic, surfacing payer requirements before submission to ensure compliance and prevent denials related to inappropriate care settings.